|
Patent landscape, scope, and claims: |
Scope and claim construction for US Patent 7,078,381 (DPIV inhibitors that modify glucose metabolism without immunosuppression), plus US patent landscape and key enforcement risks
US 7,078,381 claims methods of treating Type II diabetes and other conditions by co-administering a DPIV (dipeptidyl peptidase IV) inhibitor (including peptidomimetics and boronyl peptidomimetics) with one or more other therapeutic agents, while avoiding immune suppression through dosing and/or potency separation (glucose-metabolism effect vs immunosuppression). The strongest claim elements are (i) the DPIV inhibitor functional limitation and (ii) the “not sufficient to suppress the immune system” limitation, paired with explicit potency ratios (EC50 differential) and Ki thresholds.
What is US 7,078,381 protecting in plain terms?
Core protection (method-of-treatment / combination-use):
- Administer to an animal in need of modified glucose metabolism, a composition comprising a DPIV inhibitor (or salt).
- Dose is sufficient to modify glucose metabolism but not sufficient to suppress the immune system.
- DPIV inhibitor is administered conjointly with one or more other therapeutic agents (combination requirement).
- Claims extend to Type II diabetes treatment and to other peptide hormone metabolism modifications (within the DPIV inhibition frame).
Chemical scope within the method claims:
- DPIV inhibitors include general-Formula peptidomimetics based on:
- peptide mimetic motifs (example peptidomimetic peptides: Pro-Pro, Ala-Pro, (D)-Ala-(L)-Ala),
- broad structural formulae with heterocycles (4–8 membered),
- boronyl peptidomimetics that incorporate boronyl groups (and have separate formula sets and “small hydrophobic group” concepts),
- explicit molecular weight cutoff (< 7500 amu),
- oral administration embodiments.
Pharmacology separation is central:
- Several dependent claims define the inhibitor using in-vitro potency metrics:
- Ki for DPIV inhibition ≤ 10 nM (and tighter ≤ 1.0 nM in claim 8 for the non-boronyl set).
- EC50 for modifying glucose metabolism at least one log lower than EC50 for immunosuppression (e.g., claim 4; mirrored in other sets).
- EC50 for glucose tolerance inhibition in the nanomolar or less range (claims 5, 30, 31 depending on version).
- EC50 for immunosuppression in μM or greater range (claims 6, 32, and others in the later set).
This is not just a “DPIV inhibitor for diabetes” patent. It is a dose/potency-tailored immune-sparing combination method with broad structural coverage of inhibitors.
How do the independent claims define the protected method?
Claim 1: immune-sparing conjoint DPIV inhibition to modify glucose metabolism
- Method for modifying glucose metabolism of an animal in need.
- Conjoint administration of:
- a composition comprising a DPIV inhibitor (or pharmaceutically acceptable salt),
- in an amount sufficient to modify glucose metabolism but not sufficient to suppress immune system, and
- one or more other therapeutic agents.
- The claim is a combination dosing method with the inhibitor as an essential component.
Claim 2: immune-sparing conjoint DPIV inhibition to treat Type II diabetes
- Same architecture as claim 1 but expressly targets Type II diabetes.
Claim 25: DPIV inhibition used to modify peptide hormone metabolism (immune-sparing)
- Same “not immunosuppressive enough” concept.
- Adds that the peptide hormone is selected from:
- GHRF, VIP, PHI, PACAP, GIP, helodermin, Peptide YY, neuropeptide Y.
- This expands the “what glucose-adjacent biology gets affected” theme beyond glucose endpoints.
Claim 26: boronyl peptidomimetic DPIV inhibition to modify glucose metabolism
- Independent claim-like scope for the boronyl peptidomimetic inhibitor class for glucose metabolism, again in an immune-sparing conjoint framework.
Claim 34 and 35: glucose-intolerant animal framing and peptide-hormone half-life extension
- Claim 34: DPIV-mediated proteolysis inhibition in glucose-intolerant animals using DPIV inhibitors with Ki ≤ nanomolar (and not immunosuppressive enough), plus other therapeutic agents.
- Claim 35: DPIV inhibition increases plasma half-life of certain peptide hormones (same hormone panel) while remaining immune-sparing.
Claim 58: immune-sparing conjoint Type II diabetes treatment with explicit “Formula I” inhibitor
- Adds structural/formula-defined inhibitor coverage while retaining the immune-sparing combination architecture.
Bottom line construction: independent claims are method claims with:
- a DPIV inhibitor functional requirement (including peptidomimetic/boronyl variants),
- an immune-sparing dose limitation, and
- a combination-with-other-therapeutics requirement, and
- specific disease/endpoint recitations (glucose metabolism, Type II diabetes, and selected peptide hormones in hormone-dependent claims).
What do the dependent claims add that narrows or strengthens infringement arguments?
Potency and immune-sparing thresholds (high evidentiary leverage)
Key dependent claims are those that convert the “not suppress immune system” concept into measurable potency separation:
- Claim 4 / 38 / 29 / 38-type mirrors:
inhibitor has EC50(glucose metabolism modification) ≥ 10× lower than EC50(immunosuppression).
- Claim 5 / 39 / 30 / 31-type mirrors:
EC50 for inhibition of glucose tolerance ≤ nanomolar (or narrower “10 nM or less” in one dependent).
- Claim 6 / 40 / 32-type mirrors:
EC50 for immunosuppression ≥ μM (immune-sparing window).
- Claim 7 / 41-type mirrors:
Ki for DPIV inhibition ≤ 10 nM.
- Claim 8:
Ki for DPIV inhibition ≤ 1.0 nM.
These limitations can matter in litigation because they create testable numeric boundaries. If an accused product cannot show EC50 separations or the immunosuppression EC50 is below μM, the “immune-sparing” elements can be contested.
Structural classes: peptidomimetics and boronyl peptidomimetics
The dependent claims include multiple formula-driven limitations that substantially widen potential coverage if the formulas are broad.
- Claim 9: peptidomimetic of Pro-Pro, Ala-Pro, and (D)-Ala-(L)-Ala.
- Claim 12 / 13 / 14 / 15-type: broad general structural formulas with:
- heterocycles for ring A (4–8 member including N and Cα),
- substituted variability for substituents R1-R7, X1-X3, Y1-Y2,
- explicit allowance of pharmaceutically acceptable salts.
- Claim 16 / 49 / 61-type: “small hydrophobic group” and heterocycle closure with N and Cα motifs.
- Claim 11 / 33 / 44 / 75: inhibitor administered orally.
- Claim 10 / 43: molecular weight < 7500 amu.
- Claim 26 / 27 and the later “boronyl peptidomimetic” chain: adds a separate boronyl peptidomimetic architecture with its own formula restrictions.
Practical effect: formula claims with large variable ranges can be used offensively if the defendant’s compound falls within the defined parameter space. Defendants typically attack by:
- arguing the compound is outside the variable bounds (specific A ring size, substitution patterns, boronyl group definition),
- arguing the compound is not “represented by” the formula as construed, and/or
- attacking the numeric potency thresholds.
Combination administration timing and packaging (procedural flexibility)
Claims 77–81 are explicit “how” limitations:
- Simultaneous dosing (claim 77)
- Sequential dosing (claim 78)
- Separate dosing (claim 79)
- Same composition (claim 80)
- plus presence of pharmaceutically acceptable carrier (claim 81)
This materially weakens design-around via dosing regimen. If a regimen is structured to be “conjoint” in any practical sense, these dependent claims can be used to sweep in most real-world combination practices.
What is the factual infringement matrix implied by the claims?
For an accused product/regimen to fall within the claim set, it must generally satisfy all three buckets:
1) DPIV inhibitor identity and form
- Contains a DPIV inhibitor (or salt).
- If the formulation is asserted under formula-dependent claims, the compound must map to one of the formula classes.
2) Immune-sparing dosing window
- The amount administered is “sufficient to modify glucose metabolism” but “not sufficient to suppress immune system.”
- If numeric dependent claims are asserted, the inhibitor must show:
- EC50 separation (glucose vs immune suppression) and/or
- immunosuppression EC50 at μM or greater,
- DPIV Ki thresholds.
3) Conjoint administration with other therapeutics
- Administered with one or more other therapeutic agents.
- Timing can be simultaneous, sequential, separate, or same composition.
How broad is the claim coverage across diabetes and peptide hormone metabolism?
Diabetes endpoints
- Claims 1–2 and many dependent claims focus on:
- insulin resistance,
- glucose intolerance,
- hyperglycemia,
- hyperinsulinemia,
- obesity,
- hyperlipidemia,
- hyperlipoproteinemia.
Hormone metabolism endpoints
- Claim 25 and claim 35 cover peptide hormone metabolism modifications for a fixed hormone list. The DPIV inhibition premise links DPIV-mediated processing to hormone biology.
Claim strategy implication: Even if an accused therapy does not primarily position itself as a “glucose metabolism modifier,” the hormone-driven claims can become relevant if the DPIV inhibitor affects the specified peptide hormones and is given in the same immune-sparing conjoint combination setting.
What generic/biosimilar risk exists for this patent?
Small molecules vs “biosimilar”: DPIV inhibitors are typically small-molecule drugs; biosimilars generally do not apply. The central risk is generic small-molecule entry or non-infringing combination design.
However, this patent is method-based and includes potency separation and immune-sparing dosing concepts. That can reduce generic certainty because generics must:
- match active ingredient,
- match label-based use (or show infringement through actual use),
- potentially match the dose/exposure regime that meets the immune-sparing limitation.
Still, if the generic’s approved dosing achieves the claimed immune-sparing window and is used in combination with other therapeutics, the method claims can be asserted.
What other US patents likely interact with US 7,078,381 in the DPIV inhibitor diabetes space?
Without external bibliographic data (assignee, filing date, family members, continuations), a fully accurate “patent landscape” cannot be built from first principles. But the scope you provided indicates a landscape structure that is standard for DPIV inhibitor portfolios:
Adjacent patent categories you should expect to be in the same prosecution history or nearby families
- Chemical entity claims on DPIV inhibitor structures (peptidomimetics, boronyl peptidomimetics).
- Polymorph/salt form claims for oral DPIV inhibitors.
- Formulation claims (tablet/capsule composition; release profile).
- Use claims (Type II diabetes, glucose intolerance, immune modulation window).
- Combination therapy claims combining DPIV inhibitors with:
- insulin sensitizers,
- glucose-lowering agents (e.g., metformin class),
- incretin-pathway agents,
- lipid-lowering or obesity-associated therapies.
- Mechanism-of-action claims tied to DPIV inhibition of hormone processing and half-life extension.
Typical enforcement triangulation
In practice, method claims like this are often enforced alongside:
- compound-specific patents for the DPIV inhibitor itself, and/or
- secondary use patents that cover the exact diabetes label or specific combination use.
What claim elements are most important for freedom-to-operate (FTO) and litigation?
1) “Not sufficient to suppress the immune system” paired with EC50 separation
- This is the key differentiator versus broad “DPIV inhibitor for diabetes” use patents.
- It also creates an evidentiary battleground: assay methodology, immunosuppression proxy endpoints, and dose/exposure mapping.
2) Conjoint administration with other therapeutic agents
- This is not optional. It requires combination use.
- Most diabetes regimens are combination-like in real-world practice, so this can be difficult to avoid.
3) Numeric Ki and EC50 dependent claim thresholds
- If asserted, they require specific potency showing for the accused inhibitor.
4) Oral administration and molecular weight constraints
- “Oral” claims can be used if the accused product is oral.
- MW < 7500 amu may exclude some larger conjugates, biologics, or prodrug architectures, but likely maps to many peptide-mimetic small molecules.
Key infringement and non-infringement design paths implied by the claim language
Infringement pathways
- Using a DPIV inhibitor with demonstrated immune-sparing potency separation and giving it in combination with another therapeutic agent in a conjoint dosing regimen.
Design-around levers
- Switching to DPIV inhibitors that:
- are not within the claimed structural formulas, and/or
- do not meet the EC50 separation or Ki thresholds, and/or
- are dosed in a regimen that is not “sufficient to modify glucose metabolism” without becoming immune-suppressive (hard in practice because you need efficacy).
- Avoiding conjoint administration would be the cleanest but can be difficult:
- If “separate dosing” and “sequential dosing” are both within claim scope, “staggered regimens” likely remain at risk.
- Avoiding combination therapy entirely is the most reliable route but may compromise clinical positioning.
Key Takeaways
- US 7,078,381 protects an immune-sparing, conjoint combination method using a DPIV inhibitor to modify glucose metabolism and treat Type II diabetes, plus selected peptide hormone metabolism uses.
- The strongest narrowing features are:
- immune-sparing limitation (“not sufficient to suppress immune system”) plus
- numeric potency separation via EC50 differential and Ki/EC50 thresholds.
- The claims include broad coverage of:
- peptidomimetic DPIV inhibitors (Pro-Pro, Ala-Pro, (D)-Ala-(L)-Ala) and
- boronyl peptidomimetic inhibitors, plus large formula ranges.
- Combination dosing timing is broadly captured (simultaneous, sequential, separate, same composition), which makes regimen-based design-around harder.
- For FTO and litigation, focus on mapping the accused compound to the claimed inhibitor class and proving whether the dosing achieves the claimed immune-sparing potency window under the numeric dependent claim thresholds.
FAQs
-
Do “separate dosing” and “sequential dosing” fall within the same method claim?
Yes. The claims expressly cover simultaneous, sequential, separate dosing, and dosing in the same composition.
-
If a DPIV inhibitor is within the structural formula but causes immunosuppression at relevant doses, does infringement still occur?
Independent claims require dosing “not sufficient to suppress the immune system.” Dependent claims also add EC50 separation and μM immunosuppression thresholds.
-
What is the most litigation-relevant parameter: DPIV potency (Ki) or immune-sparing EC50?
Both. Numeric dependent claims can tie infringement to specific DPIV Ki thresholds and EC50 separation/immune-suppression EC50 cutoffs.
-
Does the patent cover peptide hormone metabolism beyond diabetes?
Yes. It includes methods for modifying metabolism of selected peptide hormones (including GHRF, VIP, PHI, PACAP, GIP, helodermin, Peptide YY, neuropeptide Y) via DPIV inhibition in an immune-sparing conjoint setting.
-
Is the claim limited to oral administration?
Not generally. Oral administration is a dependent claim. But if an accused product is oral, the oral-dependent coverage becomes relevant.
References
- US Patent 7,078,381. (Claims text as provided in prompt; method claims for DPIV inhibitors modifying glucose metabolism without immunosuppression.)
More… ↓
⤷ Start Trial
|
